Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT04794777 | Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer | recruiting | Phase 3 | 450 | Stefan CarlssonOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05169112 | Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | recruiting | Phase 3 | 72 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06641635 | Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer | recruiting | Phase 3 | 440 | Peking Union Medical College HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06870565 | Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma | not yet recruiting | Phase 3 | 238 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Mar 17, 2025 | clinicaltrials |
| NCT05440383 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | completed | Phase 3 | 287 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03525288 | PSMA-PET Guided Radiotherapy(PSMA-PETgRT) | active not recruiting | Phase 2 / Phase 3 | 130 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04557501 | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer(PATRON) | active not recruiting | Phase 3 | 800 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | terminated | Phase 3 | 86 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06565247 | Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation | recruiting | Phase 3 | 60 | Region VästerbottenOTHER_GOV | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06855589 | Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.(PCS-XII) | not yet recruiting | Phase 3 | 400 | Charles LeMoyne HospitalOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT04186819 | Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. | completed | Phase 3 | 356 | Blue Earth DiagnosticsINDUSTRY | 4 | Feb 26, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT06364904 | A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | not yet recruiting | Phase 3 | 210 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06696794 | Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients | recruiting | Phase 3 | 180 | Shaogang WangOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03013946 | Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy(PREPARE) | terminated | Phase 3 | 121 | AIO-Studien-gGmbHOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02951325 | Bladder Cancer Adjuvant Radiotherapy Trial(BART) | active not recruiting | Phase 3 | 153 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03632798 | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer(ACSCO) | withdrawn | Phase 3 | 0 | Cordgenics, LLCINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03862170 | Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer(BRP30) | terminated | Phase 3 | 158 | CR-CSSS Champlain-Charles-Le MoyneOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02891824 | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab(ATALANTE) | completed | Phase 3 | 614 | ARCAGY/ GINECO GROUPOTHER | 7 | Feb 11, 2025 | clinicaltrials |
| NCT05737303 | Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | recruiting | Phase 3 | 538 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT00104676 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors | completed | Phase 3 | 263 | UNICANCEROTHER | 3 | Feb 6, 2025 | clinicaltrials |
| NCT02446405 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer(ENZAMET) | active not recruiting | Phase 3 | 1,125 | University of SydneyOTHER | 6 | Feb 6, 2025 | clinicaltrials |
| NCT00887198 | Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,088 | Janssen Research & Development, LLCINDUSTRY | 11 | Feb 4, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT05381103 | PSMA-PET to Guide Prostatectomy | recruiting | Phase 2 / Phase 3 | 288 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT04508309 | Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls | completed | Phase 3 | 1,025 | PATHOTHER | 2 | Jan 30, 2025 | clinicaltrials |
| NCT00223145 | Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone(PCS III) | active not recruiting | Phase 3 | 600 | Abdenour NabidOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT00223171 | Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers(PCS IV) | active not recruiting | Phase 3 | 630 | Université de SherbrookeOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03103321 | Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer | completed | Phase 3 | 158 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT06781073 | Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma | completed | Phase 3 | 118 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06364631 | CARE1 Pragmatic Clinical Trial(CARE1) | recruiting | Phase 3 | 1,250 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 4 | Jan 16, 2025 | clinicaltrials |
| NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer(VISION) | completed | Phase 3 | 861 | EndocyteINDUSTRY | 10 | Jan 13, 2025 | clinicaltrials |
| NCT06768255 | Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC(mCRPC) | not yet recruiting | Phase 3 | 400 | Ding-Wei YeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06584032 | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer | recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | enrolling by invitation | Phase 2 / Phase 3 | 510 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT06751485 | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 430 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 31, 2024 | clinicaltrials |
| NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | recruiting | Phase 3 | 82 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06732635 | Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer(FAST-TRACK) | completed | Phase 3 | 68 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT02220829 | Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy | completed | Phase 3 | 148 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2025source: clinicaltrials